Equities

Spineguard SA

Spineguard SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)0.228
  • Today's Change0.006 / 2.70%
  • Shares traded20.72k
  • 1 Year change-65.69%
  • Beta0.7622
Data delayed at least 15 minutes, as of Apr 24 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SpineGuard SA is a France-based company that engages in the design and production of medical instruments used for spinal surgeries. The Company involves with the DSG (Dynamic Surgical Guidance) technology that concentrates on the placement of bone implants for the benefit of patients, surgeons, hospital staff, and healthcare systems. The DSG digital technology platform is a real-time surgical guidance work based on the measurement of local electrical conductivity of tissues without X-rays that includes PediGuard devices, the manual instruments capable of alerting surgeons in real time to potential pedicle or vertebral breaches. The technology is also implemented for the surgical robots to improve the safety, accuracy and autonomy.

  • Revenue in EUR (TTM)5.29m
  • Net income in EUR-3.23m
  • Incorporated2009
  • Employees24.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Implanet SA7.45m-6.68m8.87m41.00------1.19-0.1704-0.17040.1933-0.00420.59310.90834.19182,973.00-53.17-37.44-159.90-86.7456.8359.59-89.65-67.430.2932-24.761.03---7.242.08-88.59---2.20--
Spineguard SA5.29m-3.23m10.50m24.00--1.41--1.99-0.0899-0.08990.14890.15690.44151.476.19229,895.20-26.94-21.36-37.72-41.3874.3877.29-61.01-33.681.76-7.560.3553--27.11-7.29-38.75--55.68--
Laboratoires Euromedis SA49.54m-5.51m13.51m194.00--0.4844--0.2727-1.84-1.8416.469.700.82833.544.88255,371.10-9.19---11.45--32.67---11.09--3.57-12.830.2875---51.58---362.99------
Alpha Mos SA6.16m-3.39m15.03m48.00------2.44-0.3105-0.31050.5637-0.50660.84242.244.99128,270.80-46.70-50.01-481.38-102.4971.2768.37-55.43-74.150.4423-10.7611.30--2.257.46-39.13--7.59--
Theraclion SA1.87m-4.88m16.46m30.00--2.43--8.80-0.1362-0.13620.05040.14810.10210.2821.2366,785.00-26.65-40.08-35.36-59.9654.2152.19-260.94-276.132.50-56.170.2546---16.58-12.66-32.02--11.77--
Diagnostic Medical Systems SA37.53m3.02m18.25m120.006.561.003.360.48630.15770.02832.171.030.71461.694.58320,760.703.97-11.146.98-19.5239.4937.795.55-15.540.8608-5.700.5059---4.575.40-44.25------
Mauna Kea Technologies SA10.90m-2.17m23.28m67.00----21.642.14-0.0488-0.04880.2449-0.33860.52652.016.73194,696.40-2.61-58.19-5.19-83.9137.11-1.33-4.96-182.400.740529.852.22---2.872.2616.85---27.66--
Data as of Apr 24 2024. Currency figures normalised to Spineguard SA's reporting currency: Euro EUR

Institutional shareholders

0.22%Per cent of shares held by top holders
HolderShares% Held
Gestys SAas of 26 Jan 2024105.00k0.22%
Data from 23 Feb 2024 - 23 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.